🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Zydus Lifesciences Limited ZYDUSLIFE NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://zyduslife.com
Company Profile ↓
₹1,137.40
+18.24% 1Y
Mkt Cap₹1.14 L Cr
P/E22.71
P/B4.20
Div. Yield0.09%
52W High₹1,159.00
52W Low₹860.60
Book Value₹269.43
EPS (TTM)₹50.09

Company Overview

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopaedic surgery, including pathologies affecting the hip and knee. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 18.6%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 19.0%.

Consistent Profit Growth

Net profit has compounded at 37.0% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 16.5% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 22.7, below the sector median of 40.0.

Healthy Margins

Maintains a net profit margin of 18.9%.

Recent Developments

  • Mar 2026 Revenue of ₹26,719.70 Cr (+18.4% YoY); net profit ₹5,040.00 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +18.4%, earnings +11.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 16.5%, profit CAGR 37.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:16.55%
1 Year:18.37%

Compounded Profit Growth

5 Years:36.99%
1 Year:11.37%

Stock Price Performance

1 Year:+18.24%
6 Months:+27.08%
3 Months:+20.49%
1 Month:+5.44%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 93% of range
₹860.60 ₹1,159.00
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)59.66 · Neutral
Price Performance
1M+5.44%
3M+20.49%
6M+27.08%
1Y+18.24%
Valuation vs Sector

P/E of 22.71 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 16.5% over 5 years.
  • Profit CAGR of 37.0% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
22.71
Industry PE
39.97
Forward P/E
24.12
PEG Ratio
-
Book Value
₹269.43
Price to Book
4.20
P/S
4.16
EV/EBITDA
17.29
Dividend Yield
0.09%

Growth (CAGR)

Revenue 5Y
16.55%
Profit 5Y
36.99%
Revenue (YoY)
18.37%
Earnings (YoY)
11.37%

Profitability & Returns

ROCE
19.04%
ROE
18.59%
ROA
9.62%
Profit Margin
18.86%
Op Margin
21.66%
Gross Margin
71.34%
EPS (Latest Qtr)
₹12.65
EPS (TTM)
₹50.09

Balance Sheet & Liquidity

Debt/Equity
0.46
Quick Ratio
0.91
Current Ratio
1.27
Debt
₹12,496.00 Cr
Total Assets
₹52,406.60 Cr
Current Assets
₹19,906.10 Cr
Working Capital
₹4,194.20 Cr

Ownership

Promoter Holding
75.18%
Chg in Prom Hold
-0.64%
FII / Inst Holding
15.06%
Chg in FII Hold
-0.05%

Financial Snapshot

Enterprise Value
₹1.14 L Cr
Total Revenue (TTM)
₹26,719.70 Cr
EBITDA
₹8,394.10 Cr
Free Cash Flow
₹-554.90 Cr
Operating Cash Flow
₹2,116.60 Cr
Shares Outstanding
₹100.62 Cr
Gross Margin
71.34%
Payout Ratio
21.96%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
8 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,562.00 55.36 ₹1.06 L Cr 0.08% 13.75% 11.74% 17.73% 14.28%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 5,011.00 Cr5,140.00 Cr4,369.00 Cr4,505.00 Cr5,534.00 Cr6,208.00 Cr-5,123.50 Cr6,290.20 Cr6,467.00 Cr6,123.00 Cr6,780.40 Cr7,434.40 Cr
Cost of Revenue -------1,583.40 Cr1,697.10 Cr1,789.50 Cr-1,836.30 Cr1,976.30 Cr
Gross Profit -------3,540.10 Cr4,593.10 Cr4,677.50 Cr-4,944.10 Cr5,458.10 Cr
Operating Expenses 3,755.00 Cr3,634.00 Cr3,223.00 Cr3,403.00 Cr3,903.00 Cr4,124.00 Cr-2,564.10 Cr2,666.10 Cr2,884.20 Cr4,107.00 Cr3,651.70 Cr4,057.00 Cr
Operating Income 1,077.00 Cr1,325.00 Cr962.00 Cr907.00 Cr1,425.00 Cr1,869.00 Cr-976.00 Cr1,927.00 Cr1,793.30 Cr1,714.00 Cr1,292.40 Cr1,401.10 Cr
EBITDA 1,256.00 Cr1,505.00 Cr1,146.00 Cr1,102.00 Cr1,630.00 Cr2,084.00 Cr-1,445.10 Cr1,986.50 Cr2,243.40 Cr2,016.00 Cr1,842.90 Cr2,291.10 Cr
Interest Expense 28.00 Cr18.00 Cr9.00 Cr20.00 Cr35.00 Cr32.00 Cr-32.00 Cr76.60 Cr84.70 Cr101.00 Cr129.90 Cr123.00 Cr
Pretax Income 484.00 Cr1,328.00 Cr1,006.00 Cr947.00 Cr1,550.00 Cr1,900.00 Cr-1,184.10 Cr1,672.00 Cr1,920.60 Cr1,687.00 Cr1,353.40 Cr1,659.70 Cr
Tax Provision 135.52 Cr212.48 Cr221.32 Cr217.81 Cr325.50 Cr437.00 Cr-179.50 Cr423.20 Cr434.00 Cr455.49 Cr388.30 Cr318.40 Cr
Net Income 358.00 Cr1,134.00 Cr803.00 Cr790.00 Cr1,246.00 Cr1,482.00 Cr-1,023.50 Cr1,170.90 Cr1,466.80 Cr1,239.00 Cr1,042.10 Cr1,272.50 Cr
Diluted EPS 2.9310.747.917.8011.7514.11-10.1711.6414.5812.5110.3612.65

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 8,651.00 Cr9,427.00 Cr9,376.00 Cr11,905.00 Cr13,166.00 Cr14,253.00 Cr15,102.00 Cr-16,877.80 Cr19,021.50 Cr22,573.80 Cr26,719.70 Cr
Cost of Revenue --------6,558.90 Cr6,500.40 Cr6,666.40 Cr7,659.20 Cr
Gross Profit --------10,318.90 Cr12,521.10 Cr15,907.40 Cr19,060.50 Cr
Operating Expenses 6,896.00 Cr7,095.00 Cr7,474.00 Cr9,074.00 Cr10,174.00 Cr11,455.00 Cr11,758.00 Cr-7,466.10 Cr7,981.90 Cr9,928.10 Cr13,273.90 Cr
Operating Income 1,469.00 Cr2,040.00 Cr1,529.00 Cr2,292.00 Cr2,392.00 Cr2,102.00 Cr2,619.00 Cr-2,852.80 Cr4,539.20 Cr5,979.30 Cr5,786.60 Cr
EBITDA 1,756.00 Cr2,332.00 Cr1,902.00 Cr2,831.00 Cr2,991.00 Cr2,798.00 Cr3,344.00 Cr-3,437.90 Cr5,617.00 Cr7,036.00 Cr8,394.10 Cr
Interest Expense 68.00 Cr53.00 Cr45.00 Cr91.00 Cr194.00 Cr342.00 Cr164.00 Cr-125.50 Cr44.00 Cr93.50 Cr365.00 Cr
Pretax Income 1,446.00 Cr2,099.00 Cr1,612.00 Cr2,312.00 Cr2,382.00 Cr1,495.00 Cr2,285.00 Cr-2,589.70 Cr4,808.90 Cr6,026.70 Cr6,621.10 Cr
Tax Provision 260.28 Cr167.92 Cr128.96 Cr554.88 Cr524.04 Cr313.95 Cr137.10 Cr-587.80 Cr977.50 Cr1,411.90 Cr1,594.70 Cr
Net Income 1,188.00 Cr1,964.00 Cr1,517.00 Cr1,810.00 Cr1,899.00 Cr1,204.00 Cr2,185.00 Cr-1,960.30 Cr3,859.50 Cr4,525.50 Cr5,040.00 Cr
Diluted EPS 11.2418.8914.5317.3518.0611.4920.84-19.3038.1444.9750.09

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 9,047.00 Cr10,350.00 Cr15,104.00 Cr17,783.00 Cr23,231.00 Cr23,477.00 Cr23,765.00 Cr-25,756.40 Cr29,280.80 Cr37,201.70 Cr52,406.60 Cr
Current Assets --------10,016.40 Cr11,501.40 Cr17,046.10 Cr19,906.10 Cr
Cash & Equivalents --------487.80 Cr413.00 Cr826.80 Cr855.20 Cr
Inventory --------3,413.30 Cr3,441.90 Cr3,944.00 Cr5,628.10 Cr
Receivables --------4,416.80 Cr5,220.20 Cr4,084.80 Cr5,415.70 Cr
Total Liabilities --------6,068.10 Cr7,179.20 Cr10,843.30 Cr22,824.40 Cr
Current Liabilities --------5,530.70 Cr5,341.90 Cr9,041.60 Cr15,711.90 Cr
Long Term Debt --------0003,188.00 Cr
Total Debt 2,651.00 Cr2,442.00 Cr5,207.00 Cr5,407.00 Cr7,899.00 Cr7,986.00 Cr4,584.00 Cr-1,194.90 Cr804.20 Cr3,213.20 Cr12,496.00 Cr
Total Equity 4,251.00 Cr5,699.00 Cr6,960.00 Cr8,744.00 Cr10,386.00 Cr10,375.00 Cr12,992.00 Cr-17,515.80 Cr19,829.50 Cr23,953.10 Cr27,111.40 Cr
Shares Outstanding --------101.22 Cr100.62 Cr100.62 Cr100.62 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 994.00 Cr1,894.00 Cr1,312.00 Cr919.00 Cr1,282.00 Cr2,505.00 Cr3,293.00 Cr-2,688.80 Cr3,196.30 Cr6,781.10 Cr2,116.60 Cr
Investing Cash Flow -465.00 Cr-860.00 Cr-2,872.00 Cr-974.00 Cr-3,977.00 Cr-1,012.00 Cr-835.00 Cr-1,535.00 Cr-1,475.20 Cr-8,357.80 Cr-8,296.10 Cr
Financing Cash Flow -351.00 Cr-935.00 Cr2,316.00 Cr52.00 Cr1,885.00 Cr-1,094.00 Cr-2,549.00 Cr--4,400.40 Cr-1,778.80 Cr1,995.30 Cr5,806.90 Cr
Capital Expenditure -496.00 Cr-958.00 Cr-2,935.00 Cr-1,035.00 Cr-1,046.00 Cr-888.00 Cr-847.00 Cr--1,030.90 Cr-906.60 Cr-1,693.70 Cr-2,671.50 Cr
Free Cash Flow 498.00 Cr936.00 Cr-1,623.00 Cr-116.00 Cr236.00 Cr1,617.00 Cr2,446.00 Cr-1,657.90 Cr2,289.70 Cr5,087.40 Cr-554.90 Cr
Net Change in Cash 178.00 Cr99.00 Cr756.00 Cr-3.00 Cr-811.00 Cr399.00 Cr-90.00 Cr--176.60 Cr-57.70 Cr418.60 Cr-372.60 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------61.1%65.8%70.5%71.3%
Operating Margin % 17.0%21.6%16.3%19.3%18.2%14.7%17.3%-16.9%23.9%26.5%21.7%
Net Margin % 13.7%20.8%16.2%15.2%14.4%8.4%14.5%-11.6%20.3%20.0%18.9%
ROE % 27.9%34.5%21.8%20.7%18.3%11.6%16.8%-11.2%19.5%18.9%18.6%
ROCE % --------14.1%19.0%21.2%15.8%

Shareholding Pattern

Insiders
75.18%
Institutions
15.06%
Public Float
60.69%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ZYDUSLIFE

Google News Sun, 04 Jan 2026

Owning 75% in Zydus Lifesciences Limited (NSE:ZYDUSLIFE) means that insiders are heavily invested in the company's future - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi8wFBVV95cUxQdFVBLUk4bEN1T0JDZ1BDVTd2dWFFN01JQ0gyb0JUMHNVbnVsQVFUdVRlUVRFeTI0VFMtb1VEdV9ERmJxOFJ0WS1JcVdmLVFzeG0wSVdzUnc5ZkZ0N3VOd3lFSDFBMjNjYWV1UGtoeEsxM1NvTzNDdUczaDhxNzJaRnBpZTBhbXRUcGJDLT…

Google News ue, 20 Jan 2026

Ardelyx stock soars on report of potential Zydus Life acquisition By Investing.com - Investing.com Nigeria

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOVkdkaGpyQkFQaWhVa3JBZzVxQjg2RUg0ZFQ0bkFHbjJuNDBIMGw5NGxLOEhSU2tubnpSNjQyVk53WG4tVkhvRDVaMDNzbk9tcmZrMXJTY19MSC1jeE9oOWpiUjI1UFVwenMxaDl5UHVVTWRENTZkQ2ZBeVFDa0k4VkEyRFRHcUYzWEF6YX…

Google News Wed, 20 May 2026

Zydus Life shares rise up to 7% to hit 52-week high on strong Q4 results; MOFS sees 6% upside - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxNZ1RkRWFzbUVvTHNNTXhFZ2p0VHRCYks3WDV1OVdKMmdZdXNnWFdSZ2twM0xKZV9PY21tRHZWQjlwM3N2dm92NEpIWEo5OFl6V1djNy15d3FjNXNRcFNrcVRteFExemFBRXI5enRHdGdUbW9ya1JpSmMwX3dHeDlVMFR2ZlFzOEg2TGp6MH…

Google News hu, 14 May 2026

Zydus Life Shares Soar 5% on Acquiring Assertio Holdings in US - Equitypandit

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNeERMU0FSOHBMcS03NGR6dlQwNzJORDlPTnBSc2tkT0lEV3M3Y2VMWEtsM2tnWnNtRDNaQVJxMGlQRUlBWFJLRDExakxTWk5LeHBmbW9vTXlnU2FJMUN3Xzk1WXppRFcwOFNxU2JmblRlaUJZaWNoX1c5RmtoRjgtbDJJOEo4WENZUHhsY2…

Google News Fri, 03 Jul 2026

HCL Tech, Zydus Life, Marico among buzzing stocks as SENSEX jumps over 500 pts, NIFTY50 up 0.8% in noon deals - Upstox

<a href="https://news.google.com/rss/articles/CBMi-AFBVV95cUxNUWJQd2p6bHlaem56NG94RnR0VnVHdVpCbDRyNWpRZVR0eS1Za3czRE9ZVFNXTHN4NWZnT1YyTk54SXZ5LWE1MC1CcGVJbE53cHY5azZ5eFBhN2hkRk9zWFQ2a2ROUUpMb3M3ektIUzl5cm5mcnY3OGI2dVhoelBtYUlYUndzemIxRW5nTD…

Google News hu, 14 May 2026

Zydus Life spurts as board to mull share buyback; arm signs deal to acquire Assertio - Business Standard

<a href="https://news.google.com/rss/articles/CBMi-AFBVV95cUxOZTg0bF9Bay0xOWZaSWxMVE9JRGVCcU1DTVh0YVdlNU5QTUlyQ0M2Qjg4bVR0cmNJUHFGaU55aE5ueDVvdFBuZFZLZHd5Q1lHYlZxY2JuYk1Db09NTWR3eGtrMXlSMmpkczVEbjZwWElhNnBUazdTUWRvc1NtZXJiemp5aGdIRUo5TldNTl…

ZYDUSLIFE — Frequently Asked Questions

What is the current share price of Zydus Lifesciences Limited (ZYDUSLIFE)?

As of 2026-07-15 09:52 IST, Zydus Lifesciences Limited (ZYDUSLIFE) trades at ₹1,137.40 on NSE. Its 52-week range is ₹860.60 to ₹1,159.00.

What is the market capitalisation of ZYDUSLIFE?

Zydus Lifesciences Limited (ZYDUSLIFE) has a market capitalisation of ₹1.14 L Cr on NSE.

What is the P/E ratio of ZYDUSLIFE?

ZYDUSLIFE trades at a trailing price-to-earnings (P/E) ratio of 22.71. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 4.20.

Does ZYDUSLIFE pay a dividend?

Zydus Lifesciences Limited (ZYDUSLIFE) currently offers a dividend yield of 0.09%.

What is the return on equity (ROE) of ZYDUSLIFE?

ZYDUSLIFE has a return on equity (ROE) of 18.59%. Its return on capital employed (ROCE) is 19.04%.

Is ZYDUSLIFE a good stock to buy?

This page provides a data-driven analysis of Zydus Lifesciences Limited (ZYDUSLIFE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space